Figure 6.

The RhoA/ROCK inhibitor Y-27632 improves the myogenic potential of dKO MDSCs in vitro, when co-administrated with prednisolone. In vitro myogenic assay showed that prednisolone treatment did not increase the number of Myosin Heavy Chain-positive (MHC+) myotubes (red) when compared to non-treated cells. In contrast, combined treatment with prednisolone and Y-27632 was able to significantly increase the number of MHC+ myotubes formed by dKO MDSCs. Quantification of the number of MHC+ myotubes is shown (stars).